IMMUNOSTEP mission is to develop and market innovative products that improve diagnostic and clinical research performance and we will continue to keep working every day to deliver high-quality technology in order to fight against the global health emergency by assuring reliable results.
We work under an extensive program of development and innovation, through technology licensing, collaborations and internal promotion.
A new serological test for Covid-19 antibodies with a reliability close to 100% has been recently launched to the market, developed by researchers from the Spanish Council for Scientific Research (CSIC), in collaboration with the Madrid Hospitals of La Princesa and La Paz, and produced by Immunostep. The test is based on a protein of the virus that had not been used in diagnosis before, this protein can act as an antigen to reveal the immune response against SARS-CoV-2 with a high proven accuracy.
Our goal is to improve serology testing performance by innovating and adapting new technology to collaborate building meaningful clinical investigation.
We strongly believe validity and realiability of assessment methods must be the most important characteristics of a well- designed assessment procedure, and so we build our workflows in order to achieve the highest quality in all our products and devices.
Detecting SARS-CoV-2 immune response with an stimated accuracy of nearly 100%.
High sensitivity and specifity targeting a new exclusive non-structural protein: Cysteine-like Protease (Mpro).
Very early antibody detection from the symptoms onset identifying IgG and IgA immunoglobulins.
The Mpro protease plays a vital role in processing the polyproteins that are translated from the viral RNA. Although this protein is not exposed in the viral particle, Mpro is elicited after viral infection. Like other b-coronaviruses, SARS-CoV-2 is a positive-sense RNA virus that expresses multiple proteins as a single polypeptide chain, and Mpro cleaves the polyprotein to release mature proteins for the virus. Inhibitors that can block viral replication are promising potential drug candidates that could be used to treat patients suffering from the COVID-19 coronavirus infection.
CE/IVD kits are only suitable for clinical use in European Union and countries with EU conformity recognition agreements. Manufactured in Spain by Immunostep under CSIC Patent Licence.